From clinical stages to FDA-approved gene therapies: At the 2023 CAR-TCR Summit in Boston, bluebird bio and Lonza took the opening plenary stage to share the unique story of our 10-year journey commercializing two gene therapies.

Ten years ago, in January 2013, bluebird bio and Lonza embarked on a journey to commercialize two gene therapies. Watch the video of the plenary, featuring Kelly Kral, Vice President of CMC Strategy and Operations at bluebird Bio and Anthony Basile, Associate Director, Account Management at Lonza.

From the first Master Service Agreements for viral vectors and cell therapy manufacturing, to the inauguration of the commercial site in Pearland, Houston (TX), the Pre-Approval Inspections and the FDA approvals, in August and September 2022, of ZYNTEGLO® (betibeglogene autotemcel) and SKYSONA® (elivaldogene autotemcel), Kelly and Anthony reminisce on the highlights of this exceptional journey together.

Watch this video

Watch now
Latest content
Latest briefing from the Knowledge Center